79 systematic reviews have been added to DARE
9 economic evaluations have been added to NHSEED
1 summary of a health technology assessment has been added to the HTA database
Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia
Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase
Efficacy of surgery and imatinib mesylate in the treatment of advanced gastrointestinal stromal tumor: a systematic review
